# Case report of distal gastrectomy applied in primary duodenal bulb adenocarcinoma

**Authors:** Jin Xiang, Yuan Li, Biao Zheng, Qingqun Yi

PMC · DOI: 10.3389/fsurg.2025.1599159 · Frontiers in Surgery · 2025-10-10

## TL;DR

A rare case of duodenal bulb cancer was successfully treated with distal gastrectomy and chemotherapy, avoiding a more invasive surgery.

## Contribution

Presents a successful alternative treatment for duodenal bulb adenocarcinoma using distal gastrectomy instead of standard surgery.

## Key findings

- The patient remained disease-free for 3 years after distal gastrectomy and CapeOX chemotherapy.
- Distal gastrectomy achieved complete tumor resection with acceptable morbidity in this case.
- Mismatch repair proteins were intact in the tumor, indicating no microsatellite instability.

## Abstract

Primary duodenal bulb adenocarcinoma (PDA) is a rare and aggressive malignancy, frequently misdiagnosed due to its nonspecific clinical presentation and the lack of reliable biomarkers. While pancreaticoduodenectomy (PD) remains the standard radical treatment, its high complication rates have prompted the search for alternative therapeutic strategies.

We report the case of a 51-year-old male presenting with recurrent gastrointestinal bleeding and severe anemia, initially misdiagnosed as a benign duodenal bulb ulcer perforation. After conservative management failed, the patient underwent laparoscopic distal gastrectomy with gastrojejunostomy. Postoperative pathological examination confirmed poorly differentiated adenocarcinoma (pT4N1M0) with intact mismatch repair proteins (MLH1/MSH2/MSH6/PMS2+). The patient completed 8 cycles of CapeOX chemotherapy and remained disease-free for 3 years.

This case highlights the diagnostic challenges associated with ulcer-mimicking PDA of the duodenal bulb. Distal gastrectomy achieved complete tumor resection with acceptable morbidity, suggesting its potential as a viable alternative to PD in carefully selected cases. The combination of surgical resection and CapeOX chemotherapy yielded favorable outcomes, although long-term efficacy requires further validation.

Clinicians should consider the possibility of malignant transformation in cases of medically refractory duodenal bulb ulcers. Distal gastrectomy combined with adjuvant chemotherapy may represent a feasible treatment option for locally advanced PDA, underscoring the need for additional studies to clarify its role in therapeutic algorithms.

## Linked entities

- **Proteins:** MLH1 (mutL homolog 1), MSH2 (mutS homolog 2), MSH6 (mutS homolog 6), PMS2 (PMS1 homolog 2, mismatch repair system component)
- **Chemicals:** CapeOX (PubChem CID 71301229)
- **Diseases:** adenocarcinoma (MONDO:0004970), anemia (MONDO:0002280)

## Full-text entities

- **Genes:** MSH6 (mutS homolog 6) [NCBI Gene 2956] {aka GTBP, GTMBP, HNPCC5, HSAP, LYNCH5, MMRCS3}, MSH2 (mutS homolog 2) [NCBI Gene 4436] {aka COCA1, FCC1, HNPCC, HNPCC1, LCFS2, LYNCH1}, PMS2 (PMS1 homolog 2, mismatch repair system component) [NCBI Gene 5395] {aka HNPCC4, LYNCH4, MLH4, MMRCS4, PMS-2, PMSL2}, MLH1 (mutL homolog 1) [NCBI Gene 4292] {aka COCA2, FCC2, HNPCC, HNPCC2, LYNCH2, MLH-1}
- **Diseases:** gastrointestinal bleeding (MESH:D006471), malignancy (MESH:D009369), ulcer (MESH:D014456), anemia (MESH:D000740), PDA (MESH:D000230), duodenal bulb ulcer perforation (MESH:D004381)
- **Chemicals:** CapeOX (MESH:C519688)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12550943/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12550943/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12550943/full.md

---
Source: https://tomesphere.com/paper/PMC12550943